What we’re reading (2/9)
“Investors Await New Inflation Data Amid Tariff Concerns: What To Know This Week” (Yahoo! Finance). “In the week ahead, inflation will take center stage, with the Consumer Price Index (CPI) set for release on Wednesday morning. Updates on wholesale inflation and retail sales will also be closely tracked. On the corporate front, 78 S&P 500 companies, including McDonald's (MCD), Coca-Cola (KO), Super Micro Computer (SMCI), and Airbnb (ABNB), are set to report earnings.”
“Inside The Lovefest Between Palantir And Its Army Of Retail Investors” (Business Insider). “Karp has long eschewed the ‘rules"‘ of running a public company. He sidestepped the traditional IPO route, which relies on investment banks to market the stock to institutional investors and then gives those investors priority to buy the stock at an attractive price before retail can jump in. Instead, Palantir opted for a direct listing, which allowed retail investors to buy the stock at the same price as institutional investors when it went public. In continuing to lean into his retail fanbase, Karp often answers questions from retail investors before he addresses sell-side analysts during earnings calls. In its latest call, just two analysts—Wedbush analyst Dan Ives and Bank of America analyst Mariana Perez Mora—were given the opportunity to pitch inquiries about the business.”
“Wall Street Prepares To Defend A Favored Tax Break, Again” (DealBook). “Carried interest was one of several items Trump mentioned [this week], according to Karoline Leavitt, the White House press secretary. He reiterated ideas he promoted on the campaign trail, including ending taxes on tips, overtime and Social Security payouts, as well as expanding deductions for state and local taxes. But his call to end the carried interest exemption — and tax breaks for ‘billionaire sports-team owners’ (many of whom supported Trump) — wasn’t on many observers’ bingo cards.”
“Tommy Supreme And The Blitz” (Air Mail). “Tom Goldstein was a star in arguing cases before the Supreme Court. He was also one of the world’s highest-rolling—and most reckless—poker players. Then his worlds collided.”
“Forget Psychedelics. Everyone’s Microdosing Ozempic Now” (The Hollywood Reporter). “On a chilly January evening, Samira Shamoon, a 44-year-old health and beauty publicist, walked into an Italian restaurant to meet friends. They were stunned by the incandescence of her skin. Her cheekbones appeared more defined. After a flurry of questions about which dermatologist or plastic surgeon she had visited, she said, beaming, ‘I’m microdosing!’”
